ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 4.55B 4.12B 3.81B 3.44B 6.48B 429B 6.71B 45.8B 18.16B 229B 17.07B 16.71B 727B | P/E 2026 * |
-8.04x | P/E 2027 * | -10.2x |
|---|---|---|---|---|---|
| Enterprise Value | 4.44B 4.03B 3.72B 3.36B 6.33B 419B 6.56B 44.74B 17.74B 224B 16.68B 16.32B 710B | EV / Sales 2026 * |
4.85x | EV / Sales 2027 * | 3.85x |
| Free-Float |
99.07% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 2012-06-30 |
Brett Monia
CEO | Chief Executive Officer | 64 | 2019-12-31 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 2000-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 2005-12-12 |
| Director/Board Member | 73 | 2002-04-30 | |
Brett Monia
BRD | Director/Board Member | 64 | 2019-03-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 4.55B | |
| -2.69% | -5.28% | +58.42% | +65.89% | 68.45B | |
| -0.92% | +7.70% | +12.90% | +93.35% | 61.31B | |
| 0.00% | -0.95% | +20.09% | +99.04% | 55.73B | |
| +0.06% | +2.40% | +13.13% | +109.57% | 47.51B | |
| -1.53% | -1.79% | +19.42% | +37.85% | 44.68B | |
| -2.18% | -9.85% | +169.26% | +782.19% | 38.14B | |
| +2.15% | -0.47% | +22.85% | +56.09% | 35.85B | |
| -2.32% | -5.14% | +75.43% | +60.15% | 33.05B | |
| +2.47% | +5.99% | -36.50% | +407.36% | 25.9B | |
| Average | -0.33% | +2.41% | +39.45% | +190.17% | 46B | |
| Weighted average by Cap. | -0.74% | +2.25% | +39.51% | +163.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 916M 831M 768M 693M 1.31B 86.41B 1.35B 9.23B 3.66B 46.16B 3.44B 3.37B 147B | 1.22B 1.11B 1.03B 926M 1.74B 115B 1.81B 12.32B 4.89B 61.65B 4.59B 4.5B 196B |
| Net income | -562M -510M -471M -425M -801M -53.02B -830M -5.66B -2.25B -28.32B -2.11B -2.07B -89.91B | -439M -398M -368M -332M -625M -41.37B -647M -4.42B -1.75B -22.1B -1.65B -1.61B -70.15B |
| Net Debt | -105M -94.99M -87.86M -79.28M -149M -9.88B -155M -1.06B -419M -5.28B -393M -385M -16.76B | 163M 148M 137M 124M 233M 15.41B 241M 1.65B 653M 8.23B 613M 600M 26.13B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
